Summary
3.99 0.00(0.00%)07/01/2024
AC Immune SA (ACIU)
AC Immune SA (ACIU)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.00 | -0.74 | 3.63 | 35.14 | -17.36 | 25.79 | -27.93 | -74.46 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.99 | |
| Open | 3.90 | |
| High | 4.04 | |
| Low | 3.87 | |
| Volume | 97,911 | |
| Change | 0.00 | |
| Change % | 0.00 | |
| Avg Volume (20 Days) | 220,079 | |
| Volume/Avg Volume (20 Days) Ratio | 0.44 | |
| 52 Week Range | 2.20 - 5.13 | |
| Price vs 52 Week High | -22.22% | |
| Price vs 52 Week Low | 81.36% | |
| Range | 0.25 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 396 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 15.15 | |
| Book Value | 2.4590 | |
| Earnings Per Share | -1.0670 | |
| EPS Estimate Current Quarter | -0.3000 | |
| EPS Estimate Next Quarter | 0.1200 | |
| EPS Estimate Current Year | -0.4900 | |
| EPS Estimate Next Year | 0.0700 | |
| Diluted EPS (TTM) | -1.0670 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -79.3888 | |
| Return on asset (TTM) | -0.2037 | |
| Return on equity (TTM) | -0.3453 | |
| Revenue TTM | 944,000 | |
| Revenue per share TTM | 0.0130 | |
| Quarterly Revenue Growth (YOY) | 0.0980 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -44,056,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.8729 | |
| Revenue Enterprise Value | 172.2473 | |
| EBITDA Enterprise Value | 4.9107 | |
| Shares | ||
| Shares Outstanding | 72,652,704 | |
| Shares Float | 29,137,694 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 60.54 | |
| Institutions (%) | 27.62 | |
05/28 07:00 EST - globenewswire.com
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024. The fireside chat will take place on Wednesday, June 5 at 3:30 PM (ET).
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024. The fireside chat will take place on Wednesday, June 5 at 3:30 PM (ET).
05/13 08:47 EST - marketwatch.com
Alzheimer's vaccine licensing deal boosts AC Immune
AC Immune S.A. shares ACIU, -1.70% jumped more than 50% premarket on Monday after the Swiss biopharma company announced a licensing deal with Takeda Pharmaceutical Co. TAK, -0.90% for an experimental Alzheimer's disease vaccine.
Alzheimer's vaccine licensing deal boosts AC Immune
AC Immune S.A. shares ACIU, -1.70% jumped more than 50% premarket on Monday after the Swiss biopharma company announced a licensing deal with Takeda Pharmaceutical Co. TAK, -0.90% for an experimental Alzheimer's disease vaccine.
05/13 08:13 EST - investorplace.com
Why Is AC Immune (ACIU) Stock Up 45% Today?
AC Immune (NASDAQ: ACIU ) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company's earnings report for the first quarter of 2024. Included in that earnings report is an operational update that covers a new collaboration agreement with Takeda Pharmaceutical (NYSE: TAK ).
Why Is AC Immune (ACIU) Stock Up 45% Today?
AC Immune (NASDAQ: ACIU ) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company's earnings report for the first quarter of 2024. Included in that earnings report is an operational update that covers a new collaboration agreement with Takeda Pharmaceutical (NYSE: TAK ).
05/13 06:05 EST - globenewswire.com
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapy ACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson's disease (PD) on track for safety and immunogenicity interim data in H2 2024 Three-year cash runway with CHF 104.8 million at quarter end, plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone Lausanne, Switzerland, May 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended March 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are thrilled to have announced today our agreement with Takeda to advance ACI-24.060 anti-Abeta active immunotherapy in Alzheimer's disease (AD).
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapy ACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson's disease (PD) on track for safety and immunogenicity interim data in H2 2024 Three-year cash runway with CHF 104.8 million at quarter end, plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone Lausanne, Switzerland, May 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended March 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are thrilled to have announced today our agreement with Takeda to advance ACI-24.060 anti-Abeta active immunotherapy in Alzheimer's disease (AD).
05/13 06:00 EST - globenewswire.com
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
03/14 07:00 EST - globenewswire.com
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2 ACI-24.060 for Alzheimer's disease (AD) received FDA Fast Track designation ACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partner Cash of CHF 103 million at year end, plus the CHF 15 million milestone payment received on February 1, 2024 and the next CHF 25 million ACI-35.030-related milestone, provides funding into 2026 Lausanne, Switzerland, March 14, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer's and Parkinson's diseases.
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2 ACI-24.060 for Alzheimer's disease (AD) received FDA Fast Track designation ACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partner Cash of CHF 103 million at year end, plus the CHF 15 million milestone payment received on February 1, 2024 and the next CHF 25 million ACI-35.030-related milestone, provides funding into 2026 Lausanne, Switzerland, March 14, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer's and Parkinson's diseases.
02/22 07:00 EST - globenewswire.com
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024) Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024.
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024) Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024.
01/30 10:37 EST - zacks.com
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
01/22 07:00 EST - globenewswire.com
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab following termination of the collaboration agreements with Genentech, a member of the Roche Group, and Roche. Both antibodies have been evaluated in clinical studies for Alzheimer's disease (AD).
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab following termination of the collaboration agreements with Genentech, a member of the Roche Group, and Roche. Both antibodies have been evaluated in clinical studies for Alzheimer's disease (AD).
01/18 13:01 EST - zacks.com
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
Does AC Immune (ACIU) have what it takes to be a top stock pick for momentum investors? Let's find out.
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
Does AC Immune (ACIU) have what it takes to be a top stock pick for momentum investors? Let's find out.
01/08 11:17 EST - zacks.com
5 Small-Cap Stocks to Play the January Effect
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
5 Small-Cap Stocks to Play the January Effect
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
01/03 13:32 EST - zacks.com
AC Immune (ACIU) Upgraded to Buy: Here's Why
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AC Immune (ACIU) Upgraded to Buy: Here's Why
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
01/03 08:10 EST - globenewswire.com
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
12/18 18:25 EST - seekingalpha.com
AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts
Additional interim immunogenicity data using ACI-24.060 from the phase 1b/2 study, targeting Alzheimer's Disease patients, expected before end of 2023. 6-month amyloid plaque reduction data, from phase 1b/2 study targeting AD patients using ACI-24.060, expected 1st half of 2024. AC Immune has partnerships with major pharmaceutical companies such as Roche, Johnson & Johnson, and Eli Lilly to advance treatments for AD and other neurological disorders.
AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts
Additional interim immunogenicity data using ACI-24.060 from the phase 1b/2 study, targeting Alzheimer's Disease patients, expected before end of 2023. 6-month amyloid plaque reduction data, from phase 1b/2 study targeting AD patients using ACI-24.060, expected 1st half of 2024. AC Immune has partnerships with major pharmaceutical companies such as Roche, Johnson & Johnson, and Eli Lilly to advance treatments for AD and other neurological disorders.
12/15 07:56 EST - globenewswire.com
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, to be approximately USD 50.1 million.
AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, to be approximately USD 50.1 million.
12/15 07:22 EST - globenewswire.com
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease (AD) Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical AD AC Immune to receive approximately CHF 40 million in total milestone payments under terms of the licensing agreement, following trial initiation and enrollment milestone Lausanne, Switzerland, December 15, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms. ACI-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau).
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease (AD) Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical AD AC Immune to receive approximately CHF 40 million in total milestone payments under terms of the licensing agreement, following trial initiation and enrollment milestone Lausanne, Switzerland, December 15, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms. ACI-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau).
12/11 10:32 EST - zacks.com
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
12/05 07:31 EST - zacks.com
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
12/01 07:00 EST - globenewswire.com
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover Christopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Officer Christopher Roberts to Chief Financial Officer. Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover Christopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Officer Christopher Roberts to Chief Financial Officer. Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.